Abstract WHO grade 2 astrocytomas are defined by an IDH mutation and the absence of 1p/19q codeletion. Most harbor the canonical IDH1 R132H substitution; rarer R132X variants, including R132C, remain underrepresented in prospective trials. Vorasidenib, a brain-penetrant dual IDH1/IDH2 inhibitor, prolongs progression-fr...
Justin M. Hickey, Emily Pack, Denisse Arteaga et al.· OncoTargets and Therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.